Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

EMEA
change location▼

Search
Search

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Aug 14, 2019

Janssen Announces European Commission Approval of Imbruvica®▼(ibrutinib) for Expanded Use in Two Indications

Jul 31, 2019

Janssen Receives CHMP Positive Opinion For Stelara® (Ustekinumab) Recommending Approval For The Treatment Of Moderately To Severely Active Ulcerative Colitis In The EU

Jul 29, 2019

Janssen Submits Regulatory Application to European Medicines Agency for Rilpivirine Long Acting, to Be Used in Combination with Cabotegravir Long Acting, as the First Monthly Injectable Treatment for HIV 

Jul 22, 2019

Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX®▼ (daratumumab)

Jul 22, 2019

Janssen Reports Top-Line Phase 3 Results For Tremfya® (Guselkumab) In Adults With Active Psoriatic Arthritis

Jul 22, 2019

New data from Janssen presented at the Annual European Congress of Rheumatology (EULAR 2019) shows sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) in patients with systemic lupus erythematosus (SLE) 

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 

  • At Janssen, we have always been pioneers in innovative science, finding new and more effective ways to transform th… https://t.co/VOB7UiASH1

    2 days 21 hours ago

Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL